FDA Approves First Treatment for Spinal Muscular Atrophy

The oligonucleotide therapeutic will soon be available in the U.S.

By | December 28, 2016


The US Food and Drug Administration (FDA) on Friday (December 23) approved the first treatment for spinal muscular atrophy (SMA), a devastating neurodegenerative disorder and the leading genetic cause of death in infants. A clinical trial earlier this year demonstrated that the treatment, Spinraza (nusinersen) can improve survival and allow infants to sit, stand, or walk when they would not otherwise have been expected to.

The new treatment, developed by Biogen and Ionis Pharmaceuticals, is part of the growing class of oligonucleotide therapeutics, short strings of nucleic acids that are finding application in treating genetic disorders. SMA is caused by a defect in the splicing of a certain messenger RNA, resulting in low levels of a protein necessary for building spinal motor neurons. Infants born with the disease gradually lose their muscle function and, in severe cases, may become paralyzed or die as a result. Nusinersen treats the disease at its source, binding to the faulty section of messenger RNA to promote proper splicing.

Nusinersen is the first drug approved to treat SMA. “With the approval today of Spinraza, the future for those affected with SMA has changed,” Kenneth Hobby, president of the nonprofit Cure SMA, said in a press release

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. 2017 Top 10 Innovations
    Features 2017 Top 10 Innovations

    From single-cell analysis to whole-genome sequencing, this year’s best new products shine on many levels.

  2. Thousands of Mutations Accumulate in the Human Brain Over a Lifetime
  3. Antiviral Immunotherapy Comes of Age
    News Analysis Antiviral Immunotherapy Comes of Age

    T-cell therapies are not just for cancer. Researchers are also advancing immunotherapy methods to protect bone marrow transplant patients from viral infections. 

  4. The Rising Research Profile of 23andMe
    News Analysis The Rising Research Profile of 23andMe

    An exploration of the genetics of earlobe attachment is just the latest collaborative research project to come out of the personal genetic testing company.